Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Lehr T et al. – A quantitative EHC model was successfully developed that was capable of describing the multiple peaks in plasma concentration–time profiles of tesofensine and meloxicam very well. Additionally, the model successfully quantified the observed results for an interruption of the meloxicam EHC. The model offers an in silico method to support an EHC hypothesis using standard pharmacokinetic data and might help to guide dosing recommendations of compounds undergoing EHC.

Related Articles

Tacrolimus Population Pharmacokinetic-Pharmacogenetic Analysis and Bayesian Estimation in Renal Transplant Recipients
Clinical Pharmacokinetics, 11/24/09    Relevance Score: 91%%

Evaluation of Cynomolgus Monkey PXR, Primary Hepatocyte and In Vivo Pharmacokinetic Changes in Predicting Human CYP3A4 Induction
Drug Metabolism and Disposition, 10/21/09    Relevance Score: 89%%

Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects
British Journal of Clinical Pharmacology, 10/20/09    Relevance Score: 89%%

Antiretroviral Adherence and Pharmacokinetics: Review of their Roles in Sustained Virologic Suppression
AIDS Patient Care and STDs, 10/05/09    Relevance Score: 89%%

Pharmacokinetics after an intravenous single dose of the opioid ketobemidone in children
Acta Anaesthesiologica Scandinavica, 10/16/09    Relevance Score: 88%%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address